This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
42PRibociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). (25th November 2018)
Record Type:
Journal Article
Title:
42PRibociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). (25th November 2018)
Main Title:
42PRibociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC)